OnBioVC Releases 2009 Trend Analysis Year-in-Review Report

Share Article

Bioscience Investments Remain Active in an Environment of Overall Reduced Venture Activity. 2009 Year-in-Review Report Contains Venture Capital, M&A and IPO Data; Details 352 Deals Raising $6.3 Billion, 25 M&A Transactions Greater than $100M, and 5 Bioscience IPO's.

Bioscience venture capitalists invested $6.28 billion in 352 deals in 2009, according to the OnBioVC Trend Analysis Year-in-Review Report. Venture investments in 2009 represented a 3 percent increase in dollars and a 5 percent increase in deal volume from 2008. Investments in the fourth quarter of 2009 totaled $1.47 billion in 85 deals, a 13 percent decline in dollars and a 12 percent decrease in deals from the third quarter of 2009 when $1.66 billion went into 95 deals.

In a period where overall venture investments have declined to the lowest levels in more than a decade, bioscience investment activity in 2009 was less than 5 percent shy of the average annual investment totals for the last ten years.

Nearly one-in-ten of all bioscience venture deals closed in 2009 were in the oncology space. Financings were concentrated in mid-stage entities where 171 Series B and C deals accounted for $3.25 billion. Late-stage financings raised $1.78 billion in 68 deals representing a 37 percent increase in dollars and a 58 percent increase in deals versus 2008 where 43 deals accounted for $1.29 billion.

“Given the challenging economic environment there was evidence of an insulated focus on continued investment in biomedical innovation,” said Adam Rubenstein, Managing Editor of OnBioVC. “We are pleased to present details of the resilient 2009 bioscience venture capital market in addition to particulars on the thawing public markets and, information about twelve months of hyper-active biopharma M&A transactions, all of which are contained in the OnBioVC Trend Analysis Year-in-Review report.”

About OnBioVC
Based in Boulder, CO, OnBioVC, an Indicium Data Company, provides timely coverage and comprehensive analysis of global bioscience private and public capital investment and M&A activity. Quarterly published reports parse out transactional activity of private therapeutic, diagnostic, medical device, medical-IT and biofuel companies. The companion site, OnBioVC.com, provides deal data that is searchable by aggregate dollars raised via round, region, state, industry sector, indications and technologies as well as the venture funds participating in the individual financings. For more information please visit http://OnBioVC.com.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

ADAM RUBENSTEIN
Visit website